Fluoxetine is a potent inhibitor of coxsackievirus replication

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 9, 2012, Pages 4838-4844

  Zuo, Jun ^a   Quinn, Kevin K ^a   Kye, Steve ^a   Cooper, Paige ^a   Damoiseaux, Robert ^a   Krogstad, Paul ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; NORFLUOXETINE; VIRUS RNA;

ARTICLE; CONTROLLED STUDY; COXSACKIE VIRUS; DRUG POTENCY; DRUG SAFETY; ENTEROVIRUS INFECTION; IMMUNOBLOTTING; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS ENTRY; VIRUS REPLICATION;

ANTIDEPRESSIVE AGENTS; ANTIVIRAL AGENTS; ENTEROVIRUS; FLUOXETINE; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HELA CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INHIBITORY CONCENTRATION 50; RNA, VIRAL; SMALL MOLECULE LIBRARIES; TRANSFECTION; VIRUS REPLICATION;

EID: 84865420326     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00983-12     Document Type: Article

References (46)

1. Alderman CP, Moritz CK, Ben-Tovim DI. 1992. Abnormal platelet aggregation associated with fluoxetine therapy. Ann. Pharmacother. 26:1517-1519.
2. Barton DJ, Flanegan JB. 1997. Synchronous replication of poliovirus RNA: initiation of negative-strand RNA synthesis requires the guanidine-inhibited activity of protein 2C. J. Virol. 71:8482- 8489.
3. Beasley CM, Masica DN, Potvin JH. 1992. Fluoxetine: a review of receptor and functional effects and their clinical implications. Psychopharmacology (Berl.) 107:1-10.
4. Brown BA, Oberste MS, Alexander JP, Jr, Kennett ML, Pallansch MA. 1999. Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998. J. Virol. 73:9969 -9975.
5. Cardosa MJ, et al. 2003. Molecular epidemiology of human enterovirus 71 strains and recent outbreaks in the Asia-Pacific region: comparative analysis of the VP1 and VP4 genes. Emerg. Infect. Dis. 9:461- 468.
6. Centers for Disease Control and Prevention. 2008. Increased detections and severe neonatal disease associated with coxsackievirus B1 infection - United States, 2007. MMWR Morb. Mortal. Wkly. Rep. 57:553-556.
7. Centers for Disease Control and Prevention. 2010. Nonpolio enterovirus and human parechovirus surveillance-United States, 2006 -2008. MMWR Morb. Mortal. Wkly. Rep. 59:1577-1580.
8. Cherry JD, Krogstad PK. 2009. Enteroviruses and parechoviruses, p 1984-2041. In Feigin RD, Cherry JD, Demmler GJ, Kaplan S (ed), Textbook of pediatric infectious diseases, 6th ed. WB Saunders Co., Philadelphia, PA.
9. Chouinard G. 1985. A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. J. Clin. Psychiatry 46:32-37. (Pubitemid 15139187)
10. Corless CE, et al. 2002. Development and evaluation of a 'real-time'RT-PCR for the detection of enterovirus and parechovirus RNA in CSF and throat swab samples. J. Med. Virol. 67:555-562. (Pubitemid 34747677)
11. Dalton SO, et al. 2003. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch. Intern. Med. 163:59-64. (Pubitemid 36091601)
12. De Palma AM, Vliegen I, De Clercq E, Neyts J. 2008. Selective inhibitors of picornavirus replication. Med. Res. Rev. 28:823- 884.
13. Feuer R, Mena I, Pagarigan R, Slifka MK, Whitton JL. 2002. Cell cycle status affects coxsackievirus replication, persistence, and reactivation in vitro. J. Virol. 76:4430-4440. (Pubitemid 34309580)
14. Fry EE, Stuart DI. 2010. Virion structure, p 59-72. In Ehrenfeld DE, Roos RP (ed), The picornaviruses. ASM Press, Washington, DC.
15. Furlanut M, Soardo G, Donnini D, Sechi L, Franceschi L. 2010. Fluoxetine disposition in patients with chronic hepatitis C treated with interferon-alpha. Clin. Pharmacokinet. 49:767-772.
16. Gong E, Ivens T, Van den Eynde C, Hallenberger S, Hertogs K. 2008. Development of robust antiviral assays for profiling compounds against a panel of positive-strand RNA viruses using ATP/luminescence readout. J. Virol. Methods 151:121-125.
17. Hwang YC, Chu JJ, Yang PL, Chen W, Yates MV. 2008. Rapid identification of inhibitors that interfere with poliovirus replication using a cell-based assay. Antiviral Res. 77:232-236.
18. Jong E, et al. 2010. Predictors and treatment strategies of HIV-related fatigue in the combined antiretroviral therapy era. AIDS 24:1387-1405.
19. Khetsuriani N, Lamonte-Fowlkes A, Oberst S, Pallansch MA. 2006. Enterovirus surveillance - United States, 1970-2005. MMWR Surveill. Summ. 55:1-20.
20. Knowlton KU, Jeon ES, Berkley N, Wessely R, Huber S. 1996. A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3. J. Virol. 70:7811-7818. (Pubitemid 26339087)
21. Krogstad P, Hammon R, Halnon N, Whitton JL. 2008. Fatal neonatal myocarditis caused by a recombinant human enterovirus-B variant. Pediatr. Infect. Dis. J. 27:668-669.
22. Labos C, Dasgupta K, Nedjar H, Turecki G, Rahme E. 2011. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ 183:1835-1843.
23. Lauterbach EC. 2012. Psychotropic drug effects on gene transcriptomics relevant to Parkinson's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 38:107-115.
24. Lee MS, et al. 2010. An investigation of epidemic enterovirus 71 infection in Taiwan, 2008: clinical, virologic, and serologic features. Pediatr. Infect. Dis. J. 29:1030 -1034.
25. Lemberger L, et al. 1985. Fluoxetine: clinical pharmacology and physiologic disposition. J. Clin. Psychiatry 46:14 -19.
26. Liu CC, Tseng HW, Wang SM, Wang JR, Su IJ. 2000. An outbreak of enterovirus 71 infection in Taiwan, 1998: epidemiologic and clinical manifestations. J. Clin. Virol. 17:23-30.
27. Ma E, Chan KC, Cheng P, Wong C, Chuang SK. 2010. The enterovirus 71 epidemic in 2008 - public health implications for Hong Kong. Int. J. Infect. Dis. 14:e775- e780.
28. Millan MJ. 2011. MicroRNA in the regulation and expression of serotonergic transmission in the brain and other tissues. Curr. Opin. Pharmacol. 11:11-22.
29. Miller JP, Geng Y, Ng HL, Yang OO, Krogstad P. 2009. Packaging limits and stability of HIV-1 sequences in a coxsackievirus B vector. Vaccine 27:3992- 4000.
30. Oberste M. 2008. Comparative genomics of the coxsackie B viruses and related enteroviruses. Curr. Top. Microbiol. Immunol. 323:33- 47.
31. Oberste MS, Maher K, Pallansch MA. 2004. Evidence for frequent recombination within species human enterovirus B based on complete genomic sequences of all thirty-seven serotypes. J. Virol. 78:855- 867.
32. Oberste MS, Penaranda S, Pallansch MA. 2004. RNA recombination plays a major role in genomic change during circulation of coxsackie B viruses. J. Virol. 78:2948 -2955.
33. Pfister T, Wimmer E. 1999. Characterization of the nucleoside triphosphatase activity of poliovirus protein 2C reveals a mechanism by which guanidine inhibits poliovirus replication. J. Biol. Chem. 274:6992-7001.
34. Rotbart HA, Webster AD. 2001. Treatment of potentially life-threatening enterovirus infections with pleconaril. Clin. Infect. Dis. 32:228 -235.
35. Sacre S, Medghalchi M, Gregory B, Brennan F, Williams R. 2010. Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors. Arthritis Rheum. 62:683- 693.
36. Slifka MK, Pagarigan R, Mena I, Feuer R, Whitton JL. 2001. Using recombinant coxsackievirus B3 to evaluate the induction and protective efficacy of CD8+ T cells during picornavirus infection. J. Virol. 75:2377-2387. (Pubitemid 32147576)
37. Thibaut HJ, De Palma AM, Neyts J. 2012. Combating enterovirus replication: state-of-the-art on antiviral research. Biochem. Pharmacol. 83: 185-192.
38. Thibaut HJ, et al. 2011. Towards the design of combination therapy for the treatment of enterovirus infections. Antiviral Res. 90:213-217.
39. Tracy S, et al. 2002. Toward testing the hypothesis that group B coxsackieviruses (CVB) trigger insulin-dependent diabetes: inoculating nonobese diabetic mice with CVB markedly lowers diabetes incidence. J. Virol. 76:12097-12111. (Pubitemid 35304309)
40. Urzainqui A, Carrasco L. 1989. Degradation of cellular proteins during poliovirus infection: studies by two-dimensional gel electrophoresis. J. Virol. 63:4729-4735. (Pubitemid 19257850)
41. Venkatesan A, Sharma R, Dasgupta A. 2003. Cell cycle regulation of hepatitis C and encephalomyocarditis virus internal ribosome entry site-mediated translation in human embryonic kidney 293 cells. Virus Res. 94:85-95. (Pubitemid 36930032)
42. Verma NA, et al. 2009. Outbreak of life-threatening coxsackievirus B1 myocarditis in neonates. Clin. Infect. Dis. 49:759 -763.
43. Vrijsen R, Vanden Berghe DA, Vlietinck AJ, Boeye A. 1986. Lycorine: a eukaryotic termination inhibitor? J. Biol. Chem. 261:505-507. (Pubitemid 16161696)
44. Whitton JL, Cornell CT, Feuer R. 2005. Host and virus determinants of picornavirus pathogenesis and tropism. Nat. Rev. Microbiol. 3:765-776. (Pubitemid 41518737)
45. Wikswo ME, et al. 2009. Increased activity of Coxsackievirus B1 strains associated with severe disease among young infants in the United States, 2007-2008. Clin. Infect. Dis. 49:e44-e51.
46. Zhang JH, Chung TD, Oldenburg KR. 1999. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4:67-73. (Pubitemid 29278954)